advertisement
Abstract #55532 Published in IGR 15-4
Clinical efficacy of travoprost-timolol fixed combination on ocular hypotensive agents and ocular surface agents in Japanese glaucoma patients
Kanamoto T; Kiuchi Y; Ichioka I; Onishi T; Osada K; Kimura W; Suchiro T; Nagaya M; Hirota A; Mukai S; Miyoshi T; Yoshi HNippon Ganka Gakkai Zasshi 2013; 117: 793-798
PURPOSE: To investigate the clinical effects of travoprost-timolol fixed combination on ocular hypotensive agents, ocular surface agents and adherence in Japanese glaucoma patients. METHODS: 28 Japanese glaucoma patients, who had used topical prostaglandin F2alpha analogue (28 eyes; PG group), were assigned to treatment with travoprost-timolol fixed combination. Reduction of intraocular pressure (IOP), grades of conjuctival follicle, conjuctival injection and keratoepitheliopathy, as well as interviews for topical administration, were evaluated. 38 patients, who switched from the topical prostaglandin F2alpha analogue and a beta-blocker to travoprost-timolol fixed combination (38eyes: PG+BB group) were also evaluated in the same manner. RESULTS: While IOP was significantly reduced in the PG group, IOP was not changed in the PG+BB group. Both groups showed no significant changes in scores for conjuctival follicle, keratoepitheliopathy, or interview. CONCLUSION: These results suggest that travoprost-timolol fixed combination reduces IOP and produces low toxicity on the ocular surface.
Classification:
11.13.4 Betablocker and prostaglandin (Part of: 11 Medical treatment > 11.13 Combination therapy)
